James A. Bankson1, David L. Schwartz2,
1Department of Imaging Physics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States; 2Department of Radiation Medicine, North Shore-LIJ Health System, New Hyde Park, NY, United States
A dual-tracer multi-animal DCE-MRI platform has been used to compare response of a xenograft model of pancreatic cancer to combinations of radiation therapy and PX-478, a novel selective HIF-1a inhibitor currently in Phase I clinical trial. Six groups of eight animals were administered sham, single-agent, concurrent, or sequential therapies. Dual-tracer multi-animal DCE-MRI evaluation of vascular changes detected most pronounced response in group given combined therapy compared to controls as early as +3d after completion of therapy, preceding detectable differences in tumor growth by >7d. The dual-tracer multi-animal DCE-MRI platform enabled high-throughput evaluation of response to therapy.